A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease

Study Purpose

The primary objectives of this trial are: - To explore the pathomechanisms involved in the generation and healing of Crohn's Disease (CD) associated perianal fistulas - To understand the mode-of-action (MoA) of BI 655130 in patients with CD and draining perianal fistulas

Recruitment Criteria

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Accepts Healthy Volunteers

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Study Type
Eligible Ages 18 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion criteria

  • - 18-75 years at date of signing informed consent - Male or female patients.
Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. Restrictions regarding women of childbearing potential. Restrictions regarding contraception for female patients are not applicable for Screening Cohort.
  • - Diagnosis of clinical Crohn´s Disease ≥ 4 months prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report - Has > 1 draining perianal fistulas (> 4 weeks duration before enrolment as a complication of Crohn's Disease (CD), confirmed by Magnetic Resonance Imaging (MRI) at screening) and a clinical indication to insert a seton drainage.
For Screening Cohort a historical MRI is sufficient.
  • - Additional enterocutaneous or abdominal fistulas are permitted (except rectovaginal fistulas) - Absent, mild or moderate clinical activity with Crohn's Disease Activity Index (CDAI)< 250.
CDAI is not applicable for Screening Cohort.
  • - Demonstrated in the past inadequate response or loss of response or have had unacceptable side effects with approved doses of at least one of the following compounds: Immunosuppressive agents (e.g. thiopurines, methotrexate), TNFɑ antagonists (e.g. infliximab, adalimumab, certolizumab pegol; or respective biosimilars), vedolizumab, ustekinumab, azathioprine and / or antibiotics - Patients with family history of colorectal cancer or personal history of increased colorectal cancer risk must have had a negative ileocolorectal cancer screening within <1 year prior to screening per local guidance (otherwise to be done during screening ileocolonoscopy).
  • - Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial Gastrointestinal Exclusion Criteria (Study cohort only) - Complications of Crohn's Disease such as symptomatic strictures, functional stenosis distal from fistula(s), short gut syndrome, or any other manifestation that might require surgery, could preclude the use of the perianal disease activity (PDAI) and Crohn's Disease Activity Index (CDAI) to assess response to therapy, or would possibly confound the evaluation of benefit from treatment with BI 655130 - Rectovaginal fistulas - Anticipated to require surgical intervention for Crohn's Disease (CD)(except seton placement) - Has an abscess that the investigator feels requires drainage beyond fistula drainage with a seton (based on either clinical assessment or Magnetic Resonance Imaging (MRI)) - Any kind of bowel resection or diversion within 6 months or any other intraabdominal surgery within 3 months prior to screening.
  • - Ileostomy, colostomy or known fixed symptomatic stenosis of the intestine at screening.
  • - Positive stool examinations for C.
difficile or other intestinal pathogens < 30 days prior to screening
  • - Evidence of colonic mucosal dysplasia or colonic adenomas, unless properly removed (properly according to the investigator's assessment) - Faecal transplant ≤ 6 months before screening - Treatment with: - any non-biologic medication (incl.
cyclosporine, JAK inhibitors such as tofacitinib, tacrolimus, sirolimus, mycophenolate mofetile, S1P modulators, SMAD7 antisense inhibitors such as mongersen), other than those allowed within 30 days prior to randomisation or detectable plasma concentration
  • - any biologic treatment approved for CD (adalimumab, infliximab, certolizumab pegol, vedolizumab or ustekinumab) within 8 weeks prior to randomization - any investigational or non-approved biologic for CD (including but not limited to IL-23 inhibitors) within 12 weeks prior to randomisation or etrolizumab within 8 weeks prior to randomization - rectal 5-ASA, rectal Tacrolimus, parenteral or rectal corticosteroids (incl.
budesonide) within 2 weeks prior to randomisation
  • - any antibiotics within 1 week prior to randomisation - any prior exposure to BI 655130 - any chronic use of NSAID within 2 weeks prior to randomisation (occasional use of NSAIDs and acetaminophen for headache, arthritis, myalgias, menstrual cramps, etc., and daily use of baby or low dose (81-162.5mg) aspirin for cardiovascular prophylaxis are permitted) - any life-attenuated vaccines within 6 weeks prior to randomization Infectious Disease Exclusion Criteria (Study cohort only) - Increased risk of infectious complications (e.g. due to past organ or stem cell transplantation) - Live or attenuated vaccination within 6 weeks prior to randomization - Patients with a positive QuantiFERON TB test during screening are excluded, unless: - Patient had previous diagnosis of active or latent TB and has completed appropriate treatment per local practice/guidelines within the last 3 years and at least 6 months before first administration of trial medication under this protocol (patients may be re-screened once to meet this criterion) - Patients with suspected false positive or indeterminate QuantiFERON TB result may be re-tested once - If Quantiferon not available or providing indeterminate results after repeat testing : A tuberculin skin test reaction ≥10mm (≥5mm if receiving ≥15mg/d prednisone or its equivalent) - Relevant chronic or acute infections including active tuberculosis, human immunodeficiency virus (HIV) infection or viral hepatitis.
A patient can be re-screened if the patient was treated and is cured from the acute infection. General Exclusion Criteria (Study cohort only)
  • - Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ carcinoma of uterine cervix.
  • - Major surgery (major according to the investigator's assessment) performed within 12 weeks prior to randomization or planned during study conduct, e.g. hip replacement.
  • - Pathological safety lab parameters: haemoglobin < 8 g/dL, total white blood count (WBC) < 3000 cells/μl, neutrophils < 1000 cells/μl, thrombocytes < 100.000/μl, creatinine ≥ 2 mg/dL, total bilirubin > 2 x ULN with ratio of direct/indirect >1 (patients with Gilbert's syndrome are not excluded), Alkaline Phosphatase >3 x ULN.
  • - Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial - Previous enrolment in this trial (exception: patients of screening cohort may be enrolled in study cohort) - Currently enrolled in another investigational device or drug trial, or less than 30 days since ending another investigational device or drug trial(s), or receiving other investigational treatment(s) - Women who are pregnant, nursing, or who plan to become pregnant in the trial - Evidence of a current or previous disease, medical condition (including chronic alcohol or drug abuse) other than crohn´s disease, surgical procedure, medical examination finding (including vital signs and electrocardiogram (ECG)), or laboratory value at the screening visit outside the reference range that in the opinion of the investigator is clinically significant and would make the study participant unreliable to adhere to the protocol or to complete the trial, compromise the safety of the patient, or compromise the quality of the data - History of allergy/hypersensitivity to the systemically administered trial medication agent or its excipients or to contrast media.

Trial Details

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

Trial ID:

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Lead Sponsor
Boehringer Ingelheim

The person who is responsible for the scientific and technical direction of the entire clinical study.

Principal Investigator
Principal Investigator Affiliation N/A

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Agency Class
Overall Status Recruiting
Countries Austria, Belgium, Germany

The disease, disorder, syndrome, illness, or injury that is being studied.

Crohn Disease

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Universitätsklinikum Erlangen, Erlangen, Germany




Universitätsklinikum Erlangen

Erlangen, , 91054

UZ Leuven, Leuven, Belgium




UZ Leuven

Leuven, , 3000

Site Contact

Marc Ferrante


+32 16 34 88 56

AKH - Medical University of Vienna, Wien, Austria




AKH - Medical University of Vienna

Wien, , 1090

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation. For a full description of terms please refer to our Terms, Conditions & Privacy.